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Abstract  Human  papillomavirus  (HPV)  has  the  highest  mortality  rate  due  to  cervical  cancer
in Northeastern  Argentina.  The  aim  of  this  work  was  to  detect  and  characterize  HPV  in  samples
from the  Province  of  Corrientes,  Argentina.  HPV  detection  and  typing  was  performed  using
PCR-RFLP  on  samples  with  different  cervical  lesions  (n  =  255).  Seventeen  viruses  typiﬁed  as  HPV-
58 were  sequenced  (E6  and  E7  genes)  and  mutations  were  analyzed.  HPV  DNA  was  detected
in 56.1  %  of  the  cervical  lesions  (143/255).  Twenty-two  different  HPV  types  were  detected.
The type  most  frequently  found  among  the  total  number  of  samples  and  HPV-positive  samples
was HPV-16  (14.5  %  and  25.9  %,  respectively),  followed  by  HPV-58  (8.2  %/14.7  %,  respectively),
which is  also  considered  a  high-risk  viral  type.  Increased  severity  of  the  cytological  status  was
associated  with  greater  rates  of  HPV  detection  and,  especially,  with  the  detection  of  greater
rates of  high-risk  types.  In  addition,  the  evolutionary  dynamics  of  the  alpha-9  species  group  and
HPV-58 was  studied.  All  HPV-58  viruses  reported  in  this  work  belonged  to  lineage  A,  sublineage
A2. The  phylodynamic  analysis  indicated  that  diversiﬁcation  of  main  groups  within  lineage  A
might have  accompanied  or  preceded  human  migrations  across  the  globe.  Given  that  the  most
prevalent viruses  found  belonged  to  high-risk  HPV  types,  some  concerns  might  arise  about  the
extent of  cross  protection  of  the  vaccines  against  the  types  not  included  in  their  design.na  de  Microbiología.  Published  by  Elsevier  España,  S.L.U.  This  is
r  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/© 2015  Asociación  Argenti
an open  access  article  unde
by-nc-nd/4.0/).∗ Corresponding author.
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325-7541/© 2015 Asociación Argentina de Microbiología. Published by Elsevier España, S.L.U. This is an open access article under the CC
Y-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Detección  del  virus  del  papiloma  humano  en  Corrientes,  Argentina:  alta  prevalencia
de  genotipo  58  y  su  ﬁlodinámica
Resumen  El  virus  del  papiloma  humano  (Human  papillomavirus  [HPV])  tiene  la  mayor  tasa  de
mortalidad  por  cáncer  de  cuello  uterino  en  el  noreste  de  Argentina.  El  objetivo  de  este  trabajo
fue detectar  y  caracterizar  el  HPV  en  muestras  de  la  provincia  de  Corrientes,  Argentina.  La
detección y  la  tipiﬁcación  se  realizó  mediante  PCR-RFLP  en  muestras  con  diferentes  lesiones
cervicales  (n  =  255).  Se  secuenciaron  17  virus  tipiﬁcados  como  HPV-58  (genes  E6  y  E7)  y  se
analizaron  sus  mutaciones.  Además,  se  estudió  la  dinámica  evolutiva  de  los  virus  del  grupo  alfa-9
y, en  particular,  del  HPV-58.  Se  detectó  ADN  viral  en  el  56,1  %  de  las  lesiones  cervicales  (143/255)
y se  detectaron  22  tipos  del  HPV.  El  tipo  encontrado  con  mayor  frecuencia  entre  el  total  de
muestras y  entre  las  HPV-positivas  fue  el  HPV-16  (14,5  %/25,9  %,  respectivamente),  seguido
por el  HPV-58  (8,2  %/14,7  %,  respectivamente),  también  considerado  como  de  alto  riesgo.  El
aumento de  la  gravedad  de  las  lesiones  se  asoció  a  mayores  tasas  de  detección  del  HPV  y,  en
especial, con  mayores  tasas  de  detección  de  tipos  de  alto  riesgo.  Todos  los  HPV-58  encontrados
pertenecieron  al  linaje  A,  sublinaje  A2.  El  análisis  ﬁlodinámico  indicó  que  la  diversiﬁcación  de
los grupos  principales  dentro  del  linaje  A  podría  haber  acompan˜ado  o  precedido  las  migraciones
humanas en  todo  el  mundo.  Dado  que  los  virus  más  prevalentes  pertenecieron  a  los  tipos  del
HPV de  alto  riesgo,  podrían  surgir  interrogantes  sobre  el  alcance  de  la  protección  cruzada  de
las vacunas  contra  los  tipos  no  incluidos  en  su  disen˜o.
© 2015  Asociación  Argentina  de  Microbiología.  Publicado  por  Elsevier  España,  S.L.U.  Este  es
un artículo  Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
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The  surveillance  of  Human  papillomavirus  (HPV)  infection
is  epidemiologically  relevant  considering  the  incorpora-
tion  of  HPV  prophylactic  vaccines  in  different  countries.
In  Argentina,  where  its  general  prevalence  in  2010  was
estimated  in  20.1  %54,  vaccination  was  introduced  into  the
immunization  schedule  for  females  aged  11  years  in  201137.
Among  the  over  150  HPV  types  described,  HPV-16  pre-
dominates,  whereas  the  prevalence  of  other  HPV  types
varies  according  to  the  geographic  region5.  It  has  been
reported  that  about  70  %  of  cervical  cancers  worldwide
are  due  to  HPV-16  and  -1820,32,  which  are  the  goals  of
commercial  vaccines.  However,  there  are  still  other  preva-
lent  high-risk  HPV  types,  such  as  HPV-31,  -33,  -45  and  -5853.
In  some  provinces  of  Argentina  (Chaco,  Corrientes,  Córdoba
and  Misiones),  an  important  detection  of  HPV-33  and  HPV-58
has  been  reported2,17,22,23,51.
Although  there  have  been  several  studies  on  the  genetic
diversity  and  phylogenetics  of  HPV4,14,19,21,42,  most  of  them
focused  on  the  characterization  of  HPV-16  and  HPV-18  vari-
ants  and  their  associations  with  pathogenic  potential  and
immunogenicity18,19.
Within  HPV-58,  several  authors  have  identiﬁed  four
distinct  clusters  (A,  B,  C  and  D),  being  lineage  A  the
most  prevalent  worldwide14,19.  Reports  about  the  important
detections  of  this  high-risk  type  in  regions  of  Argentina  such
as  the  Northeast22,23,25,  which  has  the  highest  mortality  rates
due  to  cervical  cancer1,  require  a  deeper  characterization
of  viruses  of  HPV-58.
The  aim  of  this  work  was  to  study  HPV  sequences  from  the
Province  of  Corrientes,  Argentina,  especially  those  belong-
ing  to  HPV-58.  We  attempted  to  characterize  the  viruses
from  samples  taken  from  different  cervical  lesions,  their
a
p
ducleotide  changes,  phylogenetic  relationships  and  the  evo-
utionary  dynamics  of  HPV-58  in  the  context  of  the  alpha-9
apillomavirus  species.
aterials and methods
atients
amples  belonged  to  sexually  active  women  who  attended
he  Services  of  Gynecology  and  Obstetrics  at  hospitals
‘Angela  Iglesia  Llano’’  and  ‘‘José  Ramón  Vidal’’  in  the
ity  of  Corrientes,  Province  of  Corrientes,  Argentina,  during
005--2007  (n  =  255),  and  who  had  colposcopic  or  cytohisto-
ogic  ﬁndings  suggestive  of  HPV  infection  (according  to  the
ethesda  System  2001).  Epidemiological  data  were  collected
hrough  a  standardized  questionnaire.
All patients  included  in  this  study  signed  a  written
nformed  consent  and  the  study  was  approved  by  the  Ethics
ommittee  of  the  Instituto  de  Medicina  Regional  of  the
niversidad  Nacional  del  Nordeste,  Corrientes,  Argentina
Resolution  No.:  435/05).
ample  collection,  HPV  detection  and  typing
cto-  and  endocervical  samples  were  obtained  and  DNA
as  extracted  by  the  digestion  method  with  cetyltrimethyl
mmonium  bromide  (CTAB)  and  puriﬁcation  with  isoamyl
lcohol  (24:1).  DNA  quality  was  evaluated  by  PCR  tar-
eted  to  268  base  pairs  (bp)  of  the  human  beta-globin
ene  using  primers  GH20  (5′-GAAGAGCCAAGGACAGGTAC-3′)
nd  PG04  (5′-CAACTTCATCCACGTTCACC-3′)  under  conditions
reviously  described35.  Negative  samples  for  this  test  were
iscarded.  Viral  DNA  was  detected  by  PCR  using  consensus
304  H.M.  Marín  et  al.
Table  1  Human  papillomavirus  infections  stratiﬁed  by  cytological  status
Cytologya n  (%)  HPV  positive
(%)
Odd  ratio  (IC95  %)b p-Value  High-risk  HPV
positive  (%)
Odd  ratio  (IC95  %)c p-Value
RCC  63  (24.7)  12  (19.0)  5  (7.9)
ASCUS 11  (4.3)  7  (63.6)  7.4  (1.9--29.6)  0.004  2  (18.2)  2.6  (0.4--15.4)  0.298
L-SIL 152  (59.6)  98  (64.5)  7.7  (3.8--15.7)  <0.001  60  (39.5)  7.6  (2.9--20.0)  <0.001
H-SIL 18  (7.0)  16  (88.9)  34.0  (6.9--168.2)  <0.001  15  (83.3)  58.0  (12.4--270.5)  <0.001
CC 11  (4.3)  10  (90.9)  42.5  (5.0--364.8)  <0.001  10  (90.9)  116.0  (12.2--1100.0)  <0.001
Total 255 143  (56.1)  92  (36.1)
a RCC, reactive cellular changes; L-SIL, low-grade squamous intraepithelial lesion; H-SIL, high-grade squamous intraepithelial lesion;
CC, cervical cancer.
b OR for the rates of HPV detection for each cytological status in reference to the RCC status, obtained by a logistic regression analysis.
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4OR for the rates of high-risk HPV types detection for each cyto
regression analysis.
rimers  MY09/1135.  Positive  samples  were  typed  by  RFLP
nalysis,  as  previously  described3,40.
6/E7  gene  ampliﬁcation  and  sequencing
eventeen  samples  typiﬁed  as  HPV-58  were  ampliﬁed  and
equenced  in  the  E6  (nt.  110--559)  and  E7  (nt.  574--870)
enes.  They  were  ampliﬁed  by  PCR  using  primers  E6-P1/E6-
2  and  E7-P1/E7-P2  as  previously  described12.  Amplicons
ere  puriﬁed  using  the  Wizard  SV  gel  and  PCR  Clean-
p  System  extraction  kits  (Promega  Corporation,  USA)  and
equenced  in  both  directions  (3500xl  Genetic  Analyzer,
pplied  Biosystems).
tatistical  analysis
tatistical  associations  were  evaluated  with  the  chi-square
est  using  the  Epi-Info  v3.5.1  program8.  Logistic  regres-
ion  analyses  were  used  to  determine  the  odd  ratios  for
PV  detection  or  high-risk  HPV  detection  according  to  the
ytological  status  of  infections,  using  the  Infostat  v2004
rogram26.  p-values  ≤  0.05  were  considered  signiﬁcant.
utations  and  phylogenetic  analysis  of  HPV-58
equences  from  this  work  (n  =  17)  were  aligned  with  ClustalX
2.1  and  edited  with  Bioedit  v7.0.  Mutations  in  the  E6  and
7  genes  were  determined  by  comparison  with  the  prototype
enome  of  HPV-58  (GenBank  accession  number:  NC  001443).
To  classify  sequences  into  HPV-58  lineages,  a  Bayesian
hylogenetic  analysis  was  performed  using  E6  and  E7  con-
atenated  sequences.  Analysis  was  performed  using  an
ppropriate  substitution  model  estimated  with  the  jMod-
ltest  v2.1  software,  the  uncorrelated  lognormal  (UCLN)
olecular  clock  model  and  a  Bayesian  Skyline  Plot  model
mplemented  in  BEAST  v1.8.  The  Maximum  Clade  Credibil-
ty  Tree  (MCCT)  was  obtained  using  TreeAnnotator  v1.8  from
he  BEAST  package.hylodynamic  analyses
he  phylodynamic  patterns  of  the  HPV  type  58  and  the  alpha-
 species  group  of  the  genus  Alphapapillomavirus  (HPV  types
(
w
e
tal status with reference to the RCC status, obtained by a logistic
6,  31,  33,  35,  52,  58  and  67)  were  studied  using  a  Bayesian
oalescent  analysis.  Estimations  included  the  demographic
econstruction  and  the  time  to  the  most  recent  common
ncestors  (tMRCAs)  for  the  different  groups.
Datasets  included  sequences  from  all  groups  of  each
ype  (dataset  HPV-58:  154  sequences;  dataset  HPV-Alpha-
:  221  sequences)  (available  upon  request).  Analyses  were
erformed  on  the  E6  and  E7  genes,  using  an  appropriate  sub-
titution  model  and  calibration  for  each  gene.  Analyses  were
arried  out  using  the  UCLN  molecular  clock  model  and  the
kygrid  model  implemented  in  BEAST  v1.8.  A  substitution
ate  of  1.0  ×  10−7 substitutions  per  site  per  year  (s/s/y)29
r  previously  proposed  substitution  rates  for  the  E6  and
7  genes  (2.39  ×  10−8 and  1.44  ×  10−8 (s/s/y),  respectively)
ere  used  for  calibration41.  The  uncertainty  in  parameter
stimates  was  evaluated  in  the  95  % highest  posterior  density
HPD95  %)  interval.
enBank  accession  numbers
equences  reported  in  this  work  have  been  deposited  in
enBank  under  accession  numbers  KP161621  and  KP161654.
esults
PV  detection  and  typing
 total  of  255  samples  belonging  to  women  with  a  median
ge  of  29  years  (range  =  15--62)  and  mode  of  25  years  (conﬁ-
ence  interval  95  %  =  16--34)  were  collected  for  this  study.
hese  samples  were  classiﬁed  as  having  reactive  cellular
hanges  caused  by  inﬂammation  (RCC;  n  =  63,  24.7  %),  atyp-
cal  squamous  cells  of  undetermined  signiﬁcance  (ASCUS;
 =  11,  4.3  %),  low-grade  squamous  intraepithelial  lesions
LSIL;  n  =  152,  59.6  %),  high-grade  squamous  intraepithe-
ial  lesions  (HSIL;  n  =  18,  7.1  %)  and  cervical  cancer  (n  =  11,
.3  %).
HPV  DNA  was  detected  in  56.1  %  of  the  cervical  lesions
143/255).  An  increased  severity  of  the  cytological  status
as  associated  with  a  greater  rate  of  HPV  detection  and
specially,  with  a  greater  rate  of  high-risk  HPV  types  detec-
ion  (p  <  0.01)  (Table  1).
Human  papillomavirus  in  Corrientes,  Argentina  
Table  2  Distribution  of  types  by  cytological  classiﬁcation
of cases
Type  Number  of  cases
RCC  ASCUS  LSIL  HSIL  CC  Total  (%)
16  1  1  21  5  8  36  (14.1)
58 1  0  14  6  0  21  (8.2)
53 0  2  12  0  0  14  (5.5)
6 2  1  7  1  0  11  (4.3)
31 1  0  5  3  0  9  (3.5)
18 2  0  4  1  1  8  (3.1)
11 0  0  5  0  0  5  (2.0)
66 0  0  4  0  0  4  (1.6)
84 0  0  4  0  0  4  (1.6)
33 1  0  2  0  0  3  (1.2)
45 0  0  1  0  1  2  (0.8)
61 0  0  2  0  0  2  (0.8)
26 2  0  0  0  0  2  (0.8)
35 0  0  2  0  0  2  (0.8)
39 0  0  2  0  0  2  (0.8)
52 0  1  1  0  0  2  (0.8)
56 0  0  1  0  0  1  (0.4)
62 0  1  0  0  0  1  (0.4)
70 0  0  1  0  0  1  (0.4)
81 0  0  1  0  0  1  (0.4)
100 0  1  0  0  0  1  (0.4)
6+33a 0  0  1  0  0  1  (0.4)
31+45a 0  0  1  0  0  1  (0.4)
66+45a 0  0  1  0  0  1  (0.4)
66+31a 0  0  1  0  0  1  (0.4)
66+84a 0  0  1  0  0  1  (0.4)
16+31a 0  0  1  0  0  1  (0.4)
18+55a 0  0  1  0  0  1  (0.4)
11+61a 1  0  0  0  0  1  (0.4)
Indeterminate  1  0  2  0  0  3  (1.2)
Negative  51  4  54  2  1  112  (43.9)
Total 63  11  152  18  11  255
a Mixed infection.
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ATwenty-two  different  HPV  types  were  detected.  The
decreasing  order  of  the  main  types  detected,  including  their
presence  in  multiple  infections,  were  HPV-16,  -58,  -53,  -31,
-6  and  -18  (Table  2).  Multiple  infections  were  detected  in  8
samples  (3.1  %).  The  frequency  of  the  current  vaccine  viral
types  (-16,  -18,  -6,  -11)  was  44.8  %,  while  the  high-risk  and
probable  high-risk  HPV  types  not  included  in  the  vaccine
reached  33.6  %.
The  most  prevalent  types  -16  and  -58  represented  21.4
and  14.3  %  of  the  LSIL  cases  in  which  HPV  was  detected,
respectively.  HPV-58  predominated  among  the  HSIL  cases
with  HPV  detection,  reaching  37.5  %,  followed  by  HPV-16
in  the  33.3  %.  In  contrast,  HPV-58  was  not  detected  among
cervical  cancers,  while  HPV-16  was  present  in  80  %  of  them.
HPV  DNA  was  not  found  in  43.9  %  of  samples,  possibly
owing  to  low  viral  load  or  sample  degradation,  while  inde-
terminate  cases  (n  =  3)  presented  an  electrophoretic  RFLP
pattern  that  did  not  match  any  of  the  patterns  currently
taken  as  reference,  according  to  Bernard  et  al3.
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nalysis  of  mutations  in HPV-58
 deeper  molecular  characterization  of  the  HPV-58,  the  sec-
nd  most  prevalent  type  in  this  study,  was  performed  to
nalyze  changes  with  respect  to  the  prototype  virus  and
o  look  for  mutations  previously  associated  with  cervical
esions.  Seventeen  samples  from  women  (22--33  years)  with
iruses  typed  as  HPV-58  were  sequenced  along  the  E6  and
7  genes.
The  results  showed  substitutions  in  two  nucleotide  pos-
tions  in  the  450  bp  of  the  E6  gene  (0.4  %)  and  11  in  the
97  bp  of  the  E7  gene  (3.7  %).  The  genomes  grouped  into
ine  different  variants  named  COR1  to  COR9,  according  to
he  substitution  patterns,  compared  with  the  prototype  virus
Table  3).  Amino  acid  changes  were  observed  only  in  the
educed  E7  protein  sequence.
The  most  frequent  mutations  were  C307T  (E6  gene,  in
0  %  of  the  samples)  and  G694A  (G41R),  T744G,  and  A761G
G63D),  found  in  100  %  of  the  E7  sequences.  Other  seven
utations  (A542C  in  the  E6  gene  and  G634C,  G686A,  G691A,
767A,  G859A,  A866C  in  the  E7  gene)  were  also  found;  how-
ver,  their  oncogenic  potential  has  not  been  described  or
valuated  yet.
hylogenetic  and  phylodynamic  analyses
he  phylogenetic  analysis  showed  that  samples  from
orrientes  city  belonged  to  lineage  A,  sublineage  2
A2),  according  to  the  proposed  intratypic  taxonomy  of
PV-5814,19.  Moreover,  sequences  from  Corrientes  were
ntermingled  with  sequences  from  all  around  the  world:
hina,  Japan,  Taiwan,  the  USA,  Scotland  and  Costa  Rica
Fig.  1).
Two  substitution  rates  were  used  for  calibrating  the
nalyses  of  evolutionary  dynamics  of  the  alpha-9  species
roup  and  the  HPV-58.  These  alternative  hypotheses  esti-
ated  that  the  tMRCA  for  the  alpha-9  group  originated
0.5  million  years  (My)  ago  (HPD95  %  =  16.3--25.8  My)  or
.7  My  (HPD95  %  =  3.0--4.7  My)  for  the  slowest  and  the
astest  substitution  rates,  respectively,  whereas,  the  split
p  of  HPV-58  and  its  closest  cluster,  type  HPV-33,  was
ated  8.5  My  ago  (HPD95  %  =  5.4--11.5  My)  or  1.5  My  ago
HPD95  %  =  1.0--2.1  My).  Moreover,  type  16  resulted  as  the
ost  ancient  type  (∼0.8  or  0.15  My),  followed  by  types  58,
3  and  52  (∼0.6  or  ∼0.11  My)  (Fig.  2a).
A  deeper  analysis  on  type  HPV-58  indicated  that  its  diver-
iﬁcation  might  have  started  ∼0.54  or  0.11  My  years  ago,
hile  the  tMRCA  for  lineage  A  was  estimated  ∼300,000
r  ∼65,800  years  ago  (Fig.  2b).  Finally,  diversiﬁcation  of
ain  groups  within  the  lineage  A  (sublineages  A1--A3)  might
ave  started  ∼70,000--200,000  or  ∼23,900--41,000  years  ago
Fig.  2b).
iscussion
PV  is  an  important  cofactor  for  cervical  neoplasia,  and  in
rgentina  it  is  the  most  frequent  neoplasia  (20.9/100,000
omen)  after  mammary  cancer  (71.2/100,000  women)33.
rovinces  in  the  North  and  Northeastern  regions  of  the  coun-
ry  exhibit  the  highest  rates  for  cervical  cancer  mortality1,
.g.  the  Province  of  Corrientes  shows  a  mortality  rate  due
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Table  3  HPV-58  distribution  of  variants  in  LSIL  and  HSILa
E6  E7  AA  LSIL  (n  =  11)  HSIL  (n  =  6)
307  542  634  686  691  694  744  756  761  767  801  859  866
A*  C  A  G  G  G  G  T  T  G  C  C  G  A  --  --
COR1 --  --  --  --  --  A  G  --  A  --  --  --  --  G41R
G63D
2  0
COR2 T  --  --  --  --  A  G  --  A  --  --  --  --  G41R
G63D
6  2
COR3 T  -- C  -- --  A  G  --  A  --  --  --  --  D21H
G41R
G63D
1  0
COR4 T  --  --  --  A  A  G  --  A  --  --  --  --  N40D
G41R
G63D
1  0
COR5 T  -- -- --  --  A  G  C  A  --  --  --  --  G41R
G63D
0  1
COR6 T  --  --  --  --  A  G  --  A  A  --  --  --  G41R
G63D
T65K
1  0
COR7 T  --  --  --  --  A  G  --  A  --  --  A  --  G41R
G63D
A96T
0  1
COR8 T  --  --  --  --  A  G  --  A  --  A  --  --  G41R
G63D
D76E
0  1
COR9 T  C  --  A  A  A  G  --  A  --  --  A  C  G38D
N40D
G41R
G63D
A96T
Q98P
0  1
a Nucleotide sequence alignment showing the mutations in variants named COR1 to COR9. AA, amino acid changes. A*, HPV-58 reference
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fgenome (accession number NC 001443). Underlined letters indica
o  cervical  cancer  of  14/100,000  women,  which  is  three-fold
igher  than  the  rate  for  Buenos  Aires,  the  Capital  city  of  the
ountry,  and  even  exceeds  the  value  of  the  mortality  rate
ue  to  mammary  cancer  estimated  by  screening  studies  in
orrientes1,36.
The  population  under  study  gathered  women  with  a  low
ocioeconomic  status,  who  are  particularly  vulnerable  to
his  disease  due  to  reduced  access  to  prevention  and  control
rograms.
Despite  the  studies  performed  in  this  region,  the  num-
er  of  reported  cases  is  still  scarce  to  evaluate  the  role
f  high-risk  types2,22--24,47,48.  However,  it  should  be  noted
hat  we  found  a  high  diversity  of  oncogenic  types,  with
n  increased  proportion  of  high-risk  and  probable  high-
isk  types  not  included  in  the  current  vaccines.  This  is  of
oncern  since  there  are  reports  suggesting  a  limited  cross-
rotection  of  the  vaccines  against  non  vaccine  types43,50,53.
herefore,  it  is  necessary  to  strengthen  the  monitoring  of
egional  circulation  of  these  types  in  cases  of  intraepithe-
ial  lesions,  contributing  to  impact  assessment  of  current
accines  against  HPV54.
The  description  of  the  molecular  epidemiology  of  HPV
efore  the  vaccine  introduction  in  2011  will  lead  to  a  better
escription  of  the  dynamics  of  the  circulation  of  different
A
(
c
lbstitutions that result in an amino acid change.
enotypes  and  their  variants  and  also  to  a  better  understand-
ng  of  the  relationship  between  HPV  types  and  cancer  in  our
ountry,  which  is  useful  information  for  the  evaluation  of
ew  vaccine  formulations.  Further  studies  in  post-vaccinal
tages  will  allow  to  evaluate  the  dynamics  of  high-risk  HPV
ypes  and  cross  protection  among  different  types10,54. It  is
orth  noting  that  HPV-58  is  included  in  the  nonavalent  vac-
ine  V503  formulation,  which  is  still  under  evaluation16.
The  most  frequently  found  type  in  Corrientes  was  HPV-
6,  as  also  observed  all  around  the  world  in  populations
oth  with  normal  cytology  and  cervical  abnormalities5,9,34,46.
owever,  the  secondary  types  vary  depending  on  the  geo-
raphic  region  under  study.  In  this  work,  the  most  important
econdary  type  was  HPV-58,  as  also  observed  in  other  stud-
es  in  the  cities  of  Corrientes  and  Resistencia22,23.  This  result
iffers  from  the  reference  meta-analysis  conducted  by  Bruni
t  al5. on  samples  with  normal  cytology,  which  showed
hat  HPV-18  was  the  most  important  secondary  type  both
lobally  and  in  Latin  America  and  the  Caribbean.  In  dif-
erent  regions  of  the  world,  and  even  in  other  regions  of
rgentina36,39,45,  HPV-58  was  found  to  have  low  frequency
<2  %)  when  samples  with  different  grade  of  lesions  were
onsidered9,34,46. However,  HPV-58  displays  a  high  preva-
ence  in  speciﬁc  regions  of  the  world,  especially  in  Northeast
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Figure  1  Bayesian  phylogenetic  tree  of  the  E6  and  E7  sequences  of  HPV-58.  Posterior  probability  values  higher  than  0.5  are  shown
at nodes  for  relevant  groups.  Isolates  reported  in  this  work  are  shown  in  bold.  Type  HPV-33  was  used  as  outgroup.  The  country  of
F,  Bu
d
c
Horigin is  indicated  when  available  (abbreviated  in  uppercase).  B
TW, Taiwan;  ZAM,  Zambia.
Asia  (4--15  %),  Mexico  (24--28  %),  Costa  Rica  (12  %)  and  Brazil
(12--14  %)7,11,28,30,38,52.
Four  different  lineages  (A--D)  have  been  identiﬁed  within
HPV-5814,19.  All  the  viruses  reported  in  this  work  belonged
to  lineage  A,  sublineage  A2,  which  is  the  most  preva-
lent  in  the  Americas14;  none  of  them  belonged  to  lineage
D,  which  was  previously  reported  in  some  samples  from
Argentina14.
l
g
trkina  Faso;  CHI,  China;  CR,  Costa  Rica;  ITA,  Italy;  RW,  Rwanda;
HPV-58  is  considered  a  high-risk  viral  type.  However,  its
isease  impact  shows  geographic  variation,  since  cervical
ancer  and  HSIL  are  more  prevalent  in  Asian  women  with
PV-58  than  in  women  from  other  regions46.
The  association  between  pathogenicity  and  geographic
ocation  could  be  a  consequence  of  speciﬁc  genetic  back-
rounds  of  the  host  populations  but  it  could  also  be  related
o  a  differential  geographic  distribution  of  distinct  HPV
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Figure  2  Maximum  Clade  Credibility  Tree  for  the  Alpha-9  species  group  (a)  and  for  HPV  type  58  (b)  obtained  with  a  substitution
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eate of  1  ×  10−7 s/s/y.  The  time  to  the  most  recent  common  a
elevant groups  are  shown  at  nodes.ariants.  For  other  types  it  has  been  proposed  that  dif-
erent  variant  lineages  might  display  different  pathogenic
otentials31,44.  In  line  with  this  fact,  subgroups  within  lin-
age  A  of  HPV-58,  which  display  a  differential  distribution
w
s
ator  (median  and  HPD95  %)  and  posterior  probability  values  fororldwide,  could  be  related  to  different  clinical  progres-
ion.
Chan  et  al14.  proposed  to  further  investigate  the  possible
ssociation  of  oncogenicity  with  sublineage  A1  of  HPV-58  in
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Asia.  Indeed,  some  mutations  in  the  E7  gene  showed  a  trend
of  association  with  the  severity  of  the  neoplasia12. In  our
work,  we  found  no  association  between  high  pathogenicity
and  HPV-58  infections,  neither  with  the  mutations  reported
as  involved  in  this  phenotype;  however,  it  should  be  noted
that  only  sublineage  A2  was  detected  and  that  the  samples
belonged  to  women  under  35  years  old,  and  therefore  not
included  in  the  age  range  (35--64  years  old)  strongly  associ-
ated  with  progression  to  cervical  cancer32.
The  analysis  of  genome  sequences  showed  that  E7  muta-
tions  (the  only  ones  rendering  amino  acid  changes)  were
more  frequent  than  E6  mutations.  Neither  mutations  pre-
viously  associated  with  the  severity  of  neoplasia12,15,27,  nor
cervical  cancer  associated  to  HPV-58  were  found.  However,
other  mutations  not  reported  previously  (such  as  C767A
[T65K]  and  G859A  [A96T])  were  found  among  the  sam-
ples  and  deserve  further  attention  given  that  they  localize
in  a  highly  reactive  epitope  among  patients  with  cervical
cancer13.  Additional  studies  in  the  E6  protein  assessing  the
presence  of  mutations  in  the  protein  binding  motifs  PDZ
might  help  to  study  their  impact  on  the  low  oncogenicity
of  HPV-58  in  this  population49.
The  evolutionary  dynamics  of  the  alpha-9  species  group
and  particularly,  of  type  HPV-58  was  analyzed.  The  alpha-
9  species  separated  into  two  highly  supported  groups,  one
formed  by  types  16,  31,  35  and,  the  other,  by  types  33,  52,
58,  67.
Different  substitutions  rates  -- needed  for  phylody-
namic  analysis  calibration  -- have  been  proposed  for
papillomaviruses,  such  as  1.0  ×  10−7 s/s/y  (originally  pro-
posed  for  the  L1  gene  of  mucosal  HPV)29,  2.4  ×  10−8 and
1.4  ×  10−8 s/s/y  (from  the  Feline  papillomavirus  (FPV)  for
E6  and  E7  genes,  respectively)41.  The  use  of  these  rates
resulted  in  different  diversiﬁcation  times  of  the  viral  types
that  belong  to  the  alpha-9  species  group,  including  HPV-58.
For  instance,  at  type  level,  the  tMRCA  of  HPV-16,  -33,  -52
and  -58  showed  ancestral  times  within  the  last  million  years
(∼0.6  to  ∼0.8  My)  using  the  substitution  rates  proposed  by
Rector  et  al.  or  about  0.10--0.15  My  using  those  proposed  by
Halpern.  Particularly,  lineage  A  within  HPV-58  would  have
diversiﬁed  ∼65,800  or  ∼300,000  years  ago  (depending  on
the  calibration  used),  and  the  common  ancestor  of  sublin-
eages  A1--A3  could  have  been  dated  ∼40,000  or  ∼200,000
years  ago,  suggesting  that  their  dispersion  --  even  using  the
fastest  substitution  rate  --  accompanied  or  preceded  human
migration  across  the  globe6.
This  hypothesis  could  explain  the  worldwide  distribution
of  sublineage  A2,  whereas  other  factors  might  be  involved
in  the  emergence  and  dispersion  of  the  others  groups,  as
previously  proposed18.  Is  it  worth  noting  that  none  of  the
substitutions  rates  used  to  calibrate  are  proposed  for  the  E6
or  E7  genes  in  HPV,  thus  these  estimations  should  be  taken
with  caution.
Summarizing,  this  study  describes  the  molecular  epi-
demiology  of  HPV  in  a  region  of  Argentina  with  a  high
rate  for  cervical  cancer  mortality.  The  secondary  type  was
HPV-58  (after  HPV-16),  sublineage  A2.  Although  we  found
no  association  between  this  type  and  high  pathogenicity,
there  are  still  some  concerns  about  the  extent  of  cross
protection  of  the  vaccines  against  the  types  not  included
in  their  design.  In  addition,  we  described  genomic  vari-
ants  of  HPV-58  and  characterized  the  ancient  origin  of  this
1309
ype  and  its  diversiﬁcation,  in  the  context  of  the  alpha-9
apillomavirus  species  phylodynamics.
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